- Home
- BCLI
as 07-26-2024 4:00pm EST
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 37.7M | IPO Year: | N/A |
| Target Price: | $2.00 | AVG Volume (30 days): | 517.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.13 - $1.90 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Brainstorm Cell Therapeutics Inc. News
BCLI Breaking Stock News: Dive into BCLI Ticker-Specific Updates for Smart Investing
CNW Group
2 days ago
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
Zacks Small Cap Research
16 days ago
BCLI: Preparing to Initiate Phase 3b Trial of NurOwn™ Before End of 2024…
PR Newswire
a month ago
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
MT Newswires
a month ago
Brainstorm Cell Therapeutics Prices Registered Direct Offering, Concurrent Private Placement
PR Newswire
a month ago
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
PR Newswire
a month ago
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
PR Newswire
a month ago
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
PR Newswire
a month ago
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
Compare BCLI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCLI Brainstorm Cell Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.